-
Je něco špatně v tomto záznamu ?
European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives
P. Valent, K. Hartmann, P. Bonadonna, WR. Sperr, M. Niedoszytko, O. Hermine, HC. Kluin-Nelemans, K. Sotlar, G. Hoermann, B. Nedoszytko, S. Broesby-Olsen, R. Zanotti, M. Lange, M. Doubek, K. Brockow, I. Alvarez-Twose, J. Varkonyi, S. Yavuz, G....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, přehledy
- MeSH
- lidé MeSH
- mastocytóza * diagnóza terapie MeSH
- mastocyty MeSH
- předpověď MeSH
- systémová mastocytóza * diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the development of the World Health Organization classification between 2002 and 2022. In addition, the ECNM established a robust and rapidly expanding patient registry and supported the development of new prognostic scoring systems and new treatment approaches. In all projects, ECNM representatives collaborated closely with their U.S. colleagues, various patient organizations, and other scientific networks. Finally, ECNM members have started several collaborations with industrial partners, leading to the preclinical development and clinical testing of KIT-targeting drugs in systemic mastocytosis, and some of these drugs received licensing approval in recent years. All these networking activities and collaborations have strengthened the ECNM and supported our efforts to increase awareness of MC disorders and to improve diagnosis, prognostication, and therapy in patients.
Allergy Unit Verona University Hospital Verona Italy
Department of Allergology Medical University of Gdansk Gdansk Poland
Department of Biomedicine University Hospital Basel and University of Basel Basel Switzerland
Department of Dermatology and Allergy Biederstein Technical University of Munich Munich Germany
Department of Dermatology and Allergy Centre Odense University Hospital Odense Denmark
Department of Dermatology Venereology and Allergology Medical University of Gdansk Gdansk Poland
Department of Hematology and Oncology University Hospital Mannheim Mannheim Germany
Division of Allergy and Clinical Immunology University of Salerno Salerno Italy
Division of Hematology Istanbul Medical School University of Istanbul Istanbul Turkey
Guy's and St Thomas' NHS Foundation Trust Guy's Hospital London UK
Institute of Pathology Ludwig Maximilians University Munich Germany
Institute of Pathology University Hospital Salzburg Paracelsus Medical University Salzburg Austria
Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria
MLL Munich Leukemia Laboratory Munich Germany
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23011284
- 003
- CZ-PrNML
- 005
- 20230801132929.0
- 007
- ta
- 008
- 230718s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jaip.2023.02.021 $2 doi
- 035 __
- $a (PubMed)36868470
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Valent, Peter $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: peter.valent@meduniwien.ac.at
- 245 10
- $a European Competence Network on Mastocytosis (ECNM): 20-Year Jubilee, Updates, and Future Perspectives / $c P. Valent, K. Hartmann, P. Bonadonna, WR. Sperr, M. Niedoszytko, O. Hermine, HC. Kluin-Nelemans, K. Sotlar, G. Hoermann, B. Nedoszytko, S. Broesby-Olsen, R. Zanotti, M. Lange, M. Doubek, K. Brockow, I. Alvarez-Twose, J. Varkonyi, S. Yavuz, G. Nilsson, D. Radia, C. Grattan, J. Schwaab, T. Gülen, HNG. Oude Elberink, H. Hägglund, F. Siebenhaar, E. Hadzijusufovic, V. Sabato, J. Mayer, A. Reiter, A. Orfao, HP. Horny, M. Triggiani, M. Arock
- 520 9_
- $a In 2002, the European Competence Network on Mastocytosis (ECNM) was launched as a multidisciplinary collaborative initiative to increase the awareness and to improve diagnosis and management of patients with mast cell (MC) disorders. The ECNM consists of a net of specialized centers, expert physicians, and scientists who dedicate their work to MC diseases. One essential aim of the ECNM is to timely distribute all available information about the disease to patients, doctors, and scientists. In the past 20 years, the ECNM has expanded substantially and contributed successfully to the development of new diagnostic concepts, and to the classification, prognostication, and treatments of patients with mastocytosis and MC activation disorders. The ECNM also organized annual meetings and several working conferences, thereby supporting the development of the World Health Organization classification between 2002 and 2022. In addition, the ECNM established a robust and rapidly expanding patient registry and supported the development of new prognostic scoring systems and new treatment approaches. In all projects, ECNM representatives collaborated closely with their U.S. colleagues, various patient organizations, and other scientific networks. Finally, ECNM members have started several collaborations with industrial partners, leading to the preclinical development and clinical testing of KIT-targeting drugs in systemic mastocytosis, and some of these drugs received licensing approval in recent years. All these networking activities and collaborations have strengthened the ECNM and supported our efforts to increase awareness of MC disorders and to improve diagnosis, prognostication, and therapy in patients.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a mastocytóza $x diagnóza $x terapie $7 D008415
- 650 12
- $a systémová mastocytóza $x diagnóza $7 D034721
- 650 _2
- $a předpověď $7 D005544
- 650 _2
- $a mastocyty $7 D008407
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Hartmann, Karin $u Division of Allergy, Department of Dermatology, University Hospital Basel and University of Basel, Basel, Switzerland; Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland
- 700 1_
- $a Bonadonna, Patrizia $u Allergy Unit, Verona University Hospital, Verona, Italy
- 700 1_
- $a Sperr, Wolfgang R $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
- 700 1_
- $a Niedoszytko, Marek $u Department of Allergology, Medical University of Gdansk, Gdansk, Poland
- 700 1_
- $a Hermine, Olivier $u Service d'Hématologie, Imagine Institute Université de Paris, INSERM U1163, Centre National de Référence des Mastocytoses, Hôpital Necker, Assistance Publique Hôpitaux de Paris, Paris, France
- 700 1_
- $a Kluin-Nelemans, Hanneke C $u Department of Hematology, University Hospital Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Sotlar, Karl $u Institute of Pathology, University Hospital Salzburg, Paracelsus Medical University, Salzburg, Austria
- 700 1_
- $a Hoermann, Gregor $u Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; MLL Munich Leukemia Laboratory, Munich, Germany
- 700 1_
- $a Nedoszytko, Boguslaw $u Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Poland, and Invicta Fertility and Reproductive Center, Molecular Laboratory, Sopot, Poland
- 700 1_
- $a Broesby-Olsen, Sigurd $u Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
- 700 1_
- $a Zanotti, Roberta $u Section of Hematology, Multidisciplinary Outpatients Clinics for Mastocytosis, Department of Medicine, University Hospital of Verona, Verona, Italy
- 700 1_
- $a Lange, Magdalena $u Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, Gdansk, Poland
- 700 1_
- $a Doubek, Michael $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Brockow, Knut $u Department of Dermatology and Allergy Biederstein, Technical University of Munich, Munich, Germany
- 700 1_
- $a Alvarez-Twose, Ivan $u Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast) and CIBERONC, Hospital Virgen del Valle, Toledo, Spain
- 700 1_
- $a Varkonyi, Judit $u Semmelweis University, Budapest, Hungary
- 700 1_
- $a Yavuz, Selim $u Division of Hematology, Istanbul Medical School, University of Istanbul, Istanbul, Turkey
- 700 1_
- $a Nilsson, Gunnar $u Department of Medicine Solna & Mastocytosis Centre, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden; Department of Medical Sciences, Uppsala University and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden
- 700 1_
- $a Radia, Deepti $u Guy's & St. Thomas' NHS Foundation Trust, Guy's Hospital, London, UK
- 700 1_
- $a Grattan, Clive $u St. John's Institute of Dermatology, Guy's Hospital, London, UK
- 700 1_
- $a Schwaab, Juliana $u Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
- 700 1_
- $a Gülen, Theo $u Department of Respiratory Medicine and Allergy, Karolinska University Hospital Huddinge, Stockholm, Sweden; Department of Medicine Solna, Division of Immunology and Allergy, Karolinska Institutet, Stockholm, Sweden
- 700 1_
- $a Oude Elberink, Hanneke N G $u Department of Internal Medicine, Division of Allergology, University Medical Center, Groningen University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Hägglund, Hans $u Department of Medical Sciences, Uppsala University and Section of Hematology, Uppsala University Hospital, Uppsala, Sweden
- 700 1_
- $a Siebenhaar, Frank $u Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany
- 700 1_
- $a Hadzijusufovic, Emir $u Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria; Department/University Clinic for Companion Animals and Horses, University Clinic for Small Animals, Internal Medicine Small Animals, University of Veterinary Medicine, Vienna, Austria
- 700 1_
- $a Sabato, Vito $u Faculty of Medicine and Health Sciences, Department of Immunology-Allergology-Rheumatology, University of Antwerp and Antwerp University Hospital, Antwerp, Belgium
- 700 1_
- $a Mayer, Jiri $u Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Masaryk University, Brno, Czech Republic
- 700 1_
- $a Reiter, Andreas $u Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
- 700 1_
- $a Orfao, Alberto $u Servicio Central de Citometria, Centro de Investigacion del Cancer (IBMCC, CSIC/USAL) Instituto Biosanitario de Salamanca (IBSAL), CIBERONC and Department of Medicine, University of Salamanca, Salamanca, Spain
- 700 1_
- $a Horny, Hans-Peter $u Institute of Pathology, Ludwig-Maximilians-University, Munich, Germany
- 700 1_
- $a Triggiani, Massimo $u Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy
- 700 1_
- $a Arock, Michel $u Department of Hematological Biology, Pitié-Salpêtrière Hospital, Pierre et Marie Curie University (UPMC), Paris, France
- 773 0_
- $w MED00201300 $t The journal of allergy and clinical immunology. In practice $x 2213-2201 $g Roč. 11, č. 6 (2023), s. 1706-1717
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36868470 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132926 $b ABA008
- 999 __
- $a ok $b bmc $g 1963592 $s 1197549
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 11 $c 6 $d 1706-1717 $e 20230301 $i 2213-2201 $m The journal of allergy and clinical immunology. In practice $n J Allergy Clin Immunol Pract $x MED00201300
- LZP __
- $a Pubmed-20230718
